A Single Center Retrospective Study Assessing Safety And Efficacy Of Directly Acting Antiviral Agents For The Treatment Of Hepatitis-C In Kidney Transplant Recipients.

Trial Profile

A Single Center Retrospective Study Assessing Safety And Efficacy Of Directly Acting Antiviral Agents For The Treatment Of Hepatitis-C In Kidney Transplant Recipients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Dec 2016

At a glance

  • Drugs Daclatasvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Dec 2016 New trial record
    • 22 Dec 2016 Primary endpoint (Sustained virologic response (SVR) at 12 weeks) has been met, according to results published in the Transplantation journal.
    • 22 Dec 2016 Results published in the Transplantation journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top